RE:Pipeline of Drugs ... very light in CanadaRegarding Imvexxy and Bijuva, those will be launched in 2023. Lenvima and Halaven will be launched "early 2022". The Incyte drugs will be submitted in 2022, so launch likely in 2023.
I'd imagine that, for now, with many products/markets in a launch/growth phase, and with Exelon transferring over soon as well, we have our hands full with the current portfolio for the time being.
The goal is to get to get more products into the pipeline to be launched in 2023-2024. If there's a portfolio of drugs to buy that are already in the market, or some bolt-on acquisition to strengthen our platform, that's not too bad either.
By the way, nice to see the buybacks continued in December:
| Jan 5/22 | Dec 31/21 | Knight Therapeutics Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -1,021,080 | |
| Jan 5/22 | Dec 29/21 | Knight Therapeutics Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 32,415 | $5.25 |
| Jan 5/22 | Dec 24/21 | Knight Therapeutics Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 20,100 | $5.24 |
| Jan 5/22 | Dec 23/21 | Knight Therapeutics Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 44,715 | $5.24 |